Penumbra, Inc.

40th Annual J.P. Morgan Healthcare Conference

Copyright ©2022 Penumbra, Inc. All rights reserved.

Penumbra

SAFE HARBOR

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Except for historical information, certain statements in this presentation and oral statements accompanying this presentation are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the impact of the COVID-19 pandemic on our business, results of operations and financial condition; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on February 23, 2021. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

TRADEMARKS

We use CAT, Indigo, Lightning, Lightning logo, Penumbra ENGINE, Penumbra P logos, Penumbra System, RED, Thunderbolt, and other marks as trademarks in the United States and other countries. Solely for convenience, trademarks and trade names referred to in this presentation, including logos, artwork and other visual displays, may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names.

Copyright ©2022 Penumbra, Inc. All rights reserved.

3500+
Employees

~70% are Minority*

~49% are Female*

6
Large, Underpenetrated Markets

Headquartered in Alameda

Products Available in

100+
Markets

*US numbers per internal reporting December 2021

Copyright ©2022 Penumbra, Inc. All rights reserved.

Acute Limb Ischemia (Arterial)

Deep Vein Thrombosis

Ischemic Stroke

LARGE, UNDERPENETRATED MARKETS

Coronary

Pulmonary Embolism

Immersive Healthcare

Copyright ©2022 Penumbra, Inc. All rights reserved.

ACUTE LIMB ISCHEMIA (ARTERIAL)

Total
Addressable Market

259,000[a]

Patients

Current Mechanical
Thrombectomy Interventions

50,000[b]

Patients

a. Source: Gilliland C, Shah J, Martin J. Acute limb ischemia. Tech Vasc Interv Radiol. 2017;20(4):274-280; The Sage Group ALI final report; DRG Epidemiology Report. [2021 forecast number for procedures]
b. DRG Peripheral Vascular Clot Management Supplementary Data 12/15/21

Copyright ©2022 Penumbra, Inc. All rights reserved.

ACUTE LIMB ISCHEMIA (ARTERIAL)

LIGHTNING 7

Indigo® System | Computer-Aided Mechanical Aspiration

- Appropriate sizing for arteries
- Computer-aided aspiration
- Ease of use from visual and auditory signals

Copyright ©2022 Penumbra, Inc. All rights reserved.

DEEP VEIN THROMBOSIS

Total
Addressable Market

351,000[a]

Patients

Current Mechanical
Thrombectomy Interventions

23,000[b]

Patients

a. Based on internal industry research with DRG
b. DRG Peripheral Vascular Clot Management Supplementary Data 12/15/21

Copyright ©2022 Penumbra, Inc. All rights reserved.

DEEP VEIN THROMBOSIS



Copyright ©2022 Penumbra, Inc. All rights reserved.

ISCHEMIC STROKE

Total
Addressable Market

200,000[a]

Patients

Current Mechanical
Thrombectomy Interventions

60,000[b]

Patients

a. Source: internal estimate based on publications from AHA, NIH and other industry publications
b. Source: internal estimate based on publications from AHA, NIH and other industry publications [2021 forecast number for procedures]

Copyright ©2022 Penumbra, Inc. All rights reserved.

ISCHEMIC STROKE

Penumbra System®

RED™

REPERFUSION CATHETERS



RED 62 RED 68 RED 72

- Strong portfolio of best-in-class, highly-trackable aspiration catheters
- Unique, proprietary catheter architecture
- Clinical trial with paradigm-changing Thunderbolt technology

THUNDERBOLT™

Copyright ©2022 Penumbra, Inc. All rights reserved.

CORONARY

Total
Addressable Market

193,000[a]

Patients

Current
Interventions

55,000[b]

Patients

a. Source: industry publications
b. Based on internal industry research with DRG

Copyright ©2022 Penumbra, Inc. All rights reserved.

CORONARY

CHEETAH Clinical Data

99.5%
398/400
(98.2–99.9%)

Final TIMI Thrombus Grade 0
n/N (95%CI)

97.5%
390/400
(95.5–98.8%)

Final TIMI Flow Grade 3
n/N (95% CI)

0.75%
3/400
(0.2–2.2%)

Distal Embolization
n/N (95% CI)

0%
0/400

Incidence of Device-Related Adverse Events

99.8%
399/400
(98.6–100%)

Myocardial Blush Grade 3
n/N (95% CI)

Powered by Penumbra ENGINE®



CAT™ RX

- Rapid exchange catheter designed for maximized clot removal
- Large aspiration lumen
- CHEETAH Clinical Data

Copyright ©2022 Penumbra, Inc. All rights reserved.

PULMONARY EMBOLISM

Total
Addressable Market

157,000[a]

Patients

Current Mechanical
Thrombectomy Interventions

15,000[b]

Patients

a. Based on internal industry research with DRG
b. DRG Peripheral Vascular Clot Management Supplementary Data 12/15/21

Copyright ©2022 Penumbra, Inc. All rights reserved.

PULMONARY EMBOLISM

- Lightning® 12
- Best-in-class clinical evidence with EXTRACT-PE
- STRIKE-PE to provide additional clinical data
- Clinical trial randomizing patients to Lightning versus medical management
- Partnership with RapidAI®

Copyright ©2022 Penumbra, Inc. All rights reserved.

IMMERSIVE HEALTHCARE

Total
Addressable Market

50M+[a]

Patients

- Healthcare-wide VR solution
- Large installed base connected across settings
- Software platform that enables third party developers
- Healthcare compliant data security

a. Source: internal estimates; based on CDC, MedPac, PubMed and other industry publications.

Copyright ©2022 Penumbra, Inc. All rights reserved.

IMMERSIVE HEALTHCARE

[Video showing REAL i-Series and REAL y-Series]

Copyright ©2022 Penumbra, Inc. All rights reserved.

INTERVENTIONAL

1M+

Patients

IMMERSIVE HEALTHCARE

50M+

Patients

Copyright ©2022 Penumbra, Inc. All rights reserved.

GROW FROM STRENGTH

- Six large, underpenetrated markets
- Differentiated technology

Copyright ©2022 Penumbra, Inc. All rights reserved.